Literature DB >> 17685479

Adult bone marrow-derived stem cells for organ regeneration and repair.

Florian Tögel1, Christof Westenfelder.   

Abstract

Stem cells have been recognized as a potential tool for the development of innovative therapeutic strategies. There are in general two types of stem cells, embryonic and adult stem cells. While embryonic stem cell therapy has been riddled with problems of allogeneic rejection and ethical concerns, adult stem cells have long been used in the treatment of hematological malignancies. With the recognition of additional, potentially therapeutic characteristics, bone marrow-derived stem cells have become a tool in regenerative medicine. The bone marrow is an ideal source of stem cells because it is easily accessible and harbors two types of stem cells. Hematopoietic stem cells give rise to all blood cell types and have been shown to exhibit plasticity, while multipotent marrow stromal cells are the source of osteocytes, chondrocytes, and fat cells and have been shown to support and generate a large number of different cell types. This review describes the general characteristics of these stem cell populations and their current and potential future applications in regenerative medicine. 2007 Wiley-Liss, Inc

Entities:  

Mesh:

Year:  2007        PMID: 17685479     DOI: 10.1002/dvdy.21258

Source DB:  PubMed          Journal:  Dev Dyn        ISSN: 1058-8388            Impact factor:   3.780


  33 in total

1.  Adenosine A2A receptors play an active role in mouse bone marrow-derived mesenchymal stem cell development.

Authors:  Majid Katebi; Mansooreh Soleimani; Bruce N Cronstein
Journal:  J Leukoc Biol       Date:  2008-12-12       Impact factor: 4.962

Review 2.  Mesenchymal stem cells for treatment of myocardial infarction.

Authors:  Il-Kwon Ko; Byung-Soo Kim
Journal:  Int J Stem Cells       Date:  2008-11       Impact factor: 2.500

3.  Sourcing of an alternative pericyte-like cell type from peripheral blood in clinically relevant numbers for therapeutic angiogenic applications.

Authors:  Anna Blocki; Yingting Wang; Maria Koch; Anna Goralczyk; Sebastian Beyer; Nikita Agarwal; Michelle Lee; Shehzahdi Moonshi; Jean-Yves Dewavrin; Priscilla Peh; Herbert Schwarz; Kishore Bhakoo; Michael Raghunath
Journal:  Mol Ther       Date:  2014-12-12       Impact factor: 11.454

Review 4.  Strategies to enhance paracrine potency of transplanted mesenchymal stem cells in intractable neonatal disorders.

Authors:  Won Soon Park; So Yoon Ahn; Se In Sung; Jee-Yin Ahn; Yun Sil Chang
Journal:  Pediatr Res       Date:  2017-11-01       Impact factor: 3.756

Review 5.  Stem cells for heart failure in the aging heart.

Authors:  Victoria L T Ballard
Journal:  Heart Fail Rev       Date:  2010-09       Impact factor: 4.214

Review 6.  The expression and potential regulatory function of microRNAs in the pathogenesis of leiomyoma.

Authors:  Xiaoping Luo; Nasser Chegini
Journal:  Semin Reprod Med       Date:  2008-10-24       Impact factor: 1.303

7.  Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells.

Authors:  Jakub Tolar; Akemi Ishida-Yamamoto; Megan Riddle; Ron T McElmurry; Mark Osborn; Lily Xia; Troy Lund; Catherine Slattery; Jouni Uitto; Angela M Christiano; John E Wagner; Bruce R Blazar
Journal:  Blood       Date:  2008-10-27       Impact factor: 22.113

8.  Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury.

Authors:  Florian Tögel; Arthur Cohen; Ping Zhang; Ying Yang; Zhuma Hu; Christof Westenfelder
Journal:  Stem Cells Dev       Date:  2009-04       Impact factor: 3.272

9.  Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury.

Authors:  Florian Tögel; Ying Yang; Ping Zhang; Zhuma Hu; Christof Westenfelder
Journal:  Am J Physiol Renal Physiol       Date:  2008-05-14

Review 10.  Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa.

Authors:  Allison R Keith; Kirk Twaroski; Christen L Ebens; Jakub Tolar
Journal:  Expert Opin Biol Ther       Date:  2020-03-20       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.